In a closely watched case that could have major implications for the future of drug competition, Sanofi-Aventis has sued the Food and Drug Administration in bid to halt a generic version of one of its top-selling drugs, a blood thinner made from pig intestines.
Fights between brand-name and generic drugmakers and the FDA are nothing new. But this battle stands to set an important precedent for how the agency handles biologic drugs, which are derived from living organisms and account for more than $40 billion in annual sales in the United States.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
